Dell said it will acquire Insite One, a developer of applications that enables doctors to share medical images in the cloud, for an undisclosed price, reports VentureBeat.

Alcon Inc. (NYSE:ACL) is about to become part of Novartis AG (NYSE:NVS) after the companies’ boards agreed to a merger deal.Basel, Switzerland-based Novartis agreed to pay $168 per ACL share through a combination of its own shares and “a contingent value cash component,” according to a prepared statement from Alcon.That’s a 2.4 percent [...]

The U.S. Constitution’s Commerce Clause states that Congress has the power to “regulate Commerce ’ among the several States.” To supporters of health reform, the Commerce Clause is the Grinch that stole Obamacare, writes the Health Care Blog. To opponents, it might seem like a Sanity Clause.

Efforts to rein in rapidly rising healthcare costs will require new team-based payment and delivery approaches, which would demand sacrifices from hospitals, doctors and insurers, according to the Boston Globe.

Orasi Medical Inc., a University of Minnesota-bred software startup that is developing software designed to help pharmaceuticals makers speed the development of drugs targeting neurological diseases, like Alzheimer’s, has raised $1.8 million from the sale of equity. Overall, the company hopes to raise $2.6 million by December.

Novartis AG plans to seek regulatory approval within 18 months for a pioneering tablet containing an embedded microchip that sends information to your doctor about whether you took your medication and how it’s working, according to Reuters.

Novartis will pay out-of-pocket costs for patients who use its new multiple sclerosis drug Gilenya — up to $800 a month. And the drugmaker will foot the bill — up to $600 — for clinical testing and monitoring the FDA required as part of the product’s approval, according to FiercePharma.

Ohio will receive $12.5 million as part of $422 million federal settlement with drug maker Novartis AG over allegations of improper marketing and illegal kickbacks to doctors.

Swiss drugmaker Novartis just got Food and Drug Administration approval to sell the first pill that can slow the progression of multiple sclerosis. Gilenya will go head-to-head with injectable medicines, including Avonex, Tysabri and Rebif. But how much will the MS pill cost? Novartis won’t say, NPR reports.

Orasi Medical Inc. continued its string of impressive partnerships, this time striking a licensing deal with Swiss pharma giant Novartis AG.